Table 3 Incremental cost-effectiveness ratios (expressed in QALYs and LYs) at 30-years horizon: sacubitril/valsartan vs enalapril (primary analysis) and vs valsartan (secondary analysis)
Payer | Treatment | Total Costs | Total QALYs | Incremental cost | Incremental QALYs | ICER |
Social Security | enalapril | $165,785 | 4,45 | |||
valsartan | $163,631 | 4,36 | ||||
Sacubitril/valsartan | $355,897 | 4,94 | $190,113 | 0,49 | $391,158 | |
Private | enalapril | $276,770 | 4,45 | |||
valsartan | $266,033 | 4,36 | ||||
Sacubitril/valsartan | $459,839 | 4,94 | $183,069 | 0,49 | $376,665 | |
Payer | Treatment | Total Costs | Total QALYs | Incremental cost | Incremental LYs | ICER |
Social Security | enalapril | $165,785 | 5,61 | |||
valsartan | $163,631 | 5,48 | ||||
Sacubitril/valsartan | $355,897 | 6,16 | $190,113 | 0,55 | $345,283 | |
Private | enalapril | $276,770 | 5,61 | |||
valsartan | $266,033 | 5,48 | ||||
Sacubitril/valsartan | $459,839 | 6,16 | $183,069 | 0,55 | $ 332,490 |